Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm titration study of RLY5016 in heart failure with chronic kidney disease
2010-018838-45Phase 2Completed
- Sponsor
- Relypsa, Inc.
- Start
- Mar 2010
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patiromer in heart failure (HF), chronic kidney disease (CKD) and hyperkalemia, sponsored by Relypsa, Inc. Primary endpoint: Serum potassium within normal range at end of study. Started Mar 2010; status: completed.
02
Drugs
patiromer
03
Conditions
heart failure (HF)chronic kidney disease (CKD)hyperkalemia
Beyond the preview
Go deeper on 2010-018838-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018838-45.